Cargando…

348. Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy

BACKGROUND: Catheter complications, misuse, nonadherence, safety, and legal concerns often prohibit persons with a history of substance use disorder (SUD) from receiving outpatient parenteral antimicrobial therapy (OPAT). However, single center studies in the U.S. found similar rates of readmission...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Daniel, Chastain, Daniel B, Zhao, Lingyu, Zhan, Duna, Chen, Xianyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678770/
http://dx.doi.org/10.1093/ofid/ofad500.419
_version_ 1785150442133520384
author Rogers, Daniel
Chastain, Daniel B
Zhao, Lingyu
Zhan, Duna
Chen, Xianyan
author_facet Rogers, Daniel
Chastain, Daniel B
Zhao, Lingyu
Zhan, Duna
Chen, Xianyan
author_sort Rogers, Daniel
collection PubMed
description BACKGROUND: Catheter complications, misuse, nonadherence, safety, and legal concerns often prohibit persons with a history of substance use disorder (SUD) from receiving outpatient parenteral antimicrobial therapy (OPAT). However, single center studies in the U.S. found similar rates of readmission and adverse events among patients receiving OPAT regardless of SUD history. As such, we compared outcomes and complications between patients with and without a history of SUD who were treated with multiweek OPAT using claims data from multiple years across the U.S. METHODS: We used data from the IBM MarketScan Databases to identify patients who were ≥ 18 years and treated with intravenous vancomycin, daptomycin, nafcillin, oxacillin, or cefazolin for ≥ 7 days after hospital discharge between July 1, 2016 and July 31, 2020. Those with a history of end stage renal disease or Clostridioides difficile infection were excluded. Patients were separated into two cohorts based on a history of SUD using ICD-10-CM diagnosis codes prior to hospital discharge. The rates of adverse events including drug overdose and catheter complications during OPAT, all-cause readmissions within 90 days after completion of OPAT, and infection-related readmissions within 90 days after completing OPAT were compared between groups. RESULTS: Of 5903 patients included, 18% (n = 1058) had a history of SUD. Those with a history of SUD were younger than individuals without a history of SUD (47 ± 12 vs 53 ± 15 years, P < 0.0001) and there were fewer male patients in the SUD group (52% vs 56%, P = 0.02). Type 2 diabetes mellitus (43% vs 52%, P < 0.0001), arrhythmias (33% vs 31%, P = 0.152), and depression (49% vs 30%, P < 0.0001) were most common among both groups. More patients in the SUD group experienced at least one adverse event during OPAT (8% vs 5%, P = 0.004). All-cause readmissions and infection-related readmissions within 90 days after completion of OPAT were more common among patients with a history of SUD (40% vs 32%, P < 0.0001 and 27% vs 22%, P = 0.02, respectively). CONCLUSION: Patients with a history of SUD experienced higher rates of adverse events during OPAT and were more likely to require readmission for any reason, including readmissions due to infection, within 90 days after completion of OPAT. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10678770
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106787702023-11-27 348. Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy Rogers, Daniel Chastain, Daniel B Zhao, Lingyu Zhan, Duna Chen, Xianyan Open Forum Infect Dis Abstract BACKGROUND: Catheter complications, misuse, nonadherence, safety, and legal concerns often prohibit persons with a history of substance use disorder (SUD) from receiving outpatient parenteral antimicrobial therapy (OPAT). However, single center studies in the U.S. found similar rates of readmission and adverse events among patients receiving OPAT regardless of SUD history. As such, we compared outcomes and complications between patients with and without a history of SUD who were treated with multiweek OPAT using claims data from multiple years across the U.S. METHODS: We used data from the IBM MarketScan Databases to identify patients who were ≥ 18 years and treated with intravenous vancomycin, daptomycin, nafcillin, oxacillin, or cefazolin for ≥ 7 days after hospital discharge between July 1, 2016 and July 31, 2020. Those with a history of end stage renal disease or Clostridioides difficile infection were excluded. Patients were separated into two cohorts based on a history of SUD using ICD-10-CM diagnosis codes prior to hospital discharge. The rates of adverse events including drug overdose and catheter complications during OPAT, all-cause readmissions within 90 days after completion of OPAT, and infection-related readmissions within 90 days after completing OPAT were compared between groups. RESULTS: Of 5903 patients included, 18% (n = 1058) had a history of SUD. Those with a history of SUD were younger than individuals without a history of SUD (47 ± 12 vs 53 ± 15 years, P < 0.0001) and there were fewer male patients in the SUD group (52% vs 56%, P = 0.02). Type 2 diabetes mellitus (43% vs 52%, P < 0.0001), arrhythmias (33% vs 31%, P = 0.152), and depression (49% vs 30%, P < 0.0001) were most common among both groups. More patients in the SUD group experienced at least one adverse event during OPAT (8% vs 5%, P = 0.004). All-cause readmissions and infection-related readmissions within 90 days after completion of OPAT were more common among patients with a history of SUD (40% vs 32%, P < 0.0001 and 27% vs 22%, P = 0.02, respectively). CONCLUSION: Patients with a history of SUD experienced higher rates of adverse events during OPAT and were more likely to require readmission for any reason, including readmissions due to infection, within 90 days after completion of OPAT. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678770/ http://dx.doi.org/10.1093/ofid/ofad500.419 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Rogers, Daniel
Chastain, Daniel B
Zhao, Lingyu
Zhan, Duna
Chen, Xianyan
348. Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy
title 348. Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy
title_full 348. Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy
title_fullStr 348. Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy
title_full_unstemmed 348. Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy
title_short 348. Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy
title_sort 348. impact of substance use disorders on outcomes of medically insured persons receiving multiweek outpatient parenteral antimicrobial therapy
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678770/
http://dx.doi.org/10.1093/ofid/ofad500.419
work_keys_str_mv AT rogersdaniel 348impactofsubstanceusedisordersonoutcomesofmedicallyinsuredpersonsreceivingmultiweekoutpatientparenteralantimicrobialtherapy
AT chastaindanielb 348impactofsubstanceusedisordersonoutcomesofmedicallyinsuredpersonsreceivingmultiweekoutpatientparenteralantimicrobialtherapy
AT zhaolingyu 348impactofsubstanceusedisordersonoutcomesofmedicallyinsuredpersonsreceivingmultiweekoutpatientparenteralantimicrobialtherapy
AT zhanduna 348impactofsubstanceusedisordersonoutcomesofmedicallyinsuredpersonsreceivingmultiweekoutpatientparenteralantimicrobialtherapy
AT chenxianyan 348impactofsubstanceusedisordersonoutcomesofmedicallyinsuredpersonsreceivingmultiweekoutpatientparenteralantimicrobialtherapy